254 related articles for article (PubMed ID: 32546647)
1. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Ladomersky E; Zhai L; Lauing KL; Bell A; Xu J; Kocherginsky M; Zhang B; Wu JD; Podojil JR; Platanias LC; Mochizuki AY; Prins RM; Kumthekar P; Raizer JJ; Dixit K; Lukas RV; Horbinski C; Wei M; Zhou C; Pawelec G; Campisi J; Grohmann U; Prendergast GC; Munn DH; Wainwright DA
Clin Cancer Res; 2020 Oct; 26(19):5232-5245. PubMed ID: 32546647
[TBL] [Abstract][Full Text] [Related]
2. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
[TBL] [Abstract][Full Text] [Related]
3. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma.
Iorgulescu JB; Gokhale PC; Speranza MC; Eschle BK; Poitras MJ; Wilkens MK; Soroko KM; Chhoeu C; Knott A; Gao Y; Lim-Fat MJ; Baker GJ; Bonal DM; Nguyen QD; Grant GRL; Ligon KL; Sorger PK; Chiocca EA; Anderson AC; Kirschmeier PT; Sharpe AH; Freeman GJ; Reardon DA
Clin Cancer Res; 2021 Jan; 27(1):276-287. PubMed ID: 33239433
[TBL] [Abstract][Full Text] [Related]
5. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Nguyen B; Genet M; Kim M; Chen P; Mi X; Wu JD; Schipma MJ; Wray B; Griffiths J; Unwin RD; Clark SJ; Acharya R; Bao R; Horbinski C; Lukas RV; Schiltz GE; Wainwright DA
Clin Cancer Res; 2021 Dec; 27(23):6514-6528. PubMed ID: 34479957
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
Front Immunol; 2020; 11():1185. PubMed ID: 32612606
[TBL] [Abstract][Full Text] [Related]
7. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
Ladomersky E; Zhai L; Lenzen A; Lauing KL; Qian J; Scholtens DM; Gritsina G; Sun X; Liu Y; Yu F; Gong W; Liu Y; Jiang B; Tang T; Patel R; Platanias LC; James CD; Stupp R; Lukas RV; Binder DC; Wainwright DA
Clin Cancer Res; 2018 Jun; 24(11):2559-2573. PubMed ID: 29500275
[No Abstract] [Full Text] [Related]
8. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Zhai L; Ladomersky E; Lauing KL; Wu M; Genet M; Gritsina G; Győrffy B; Brastianos PK; Binder DC; Sosman JA; Giles FJ; James CD; Horbinski C; Stupp R; Wainwright DA
Clin Cancer Res; 2017 Nov; 23(21):6650-6660. PubMed ID: 28751450
[No Abstract] [Full Text] [Related]
9. Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth.
Phan T; Nguyen VH; D'Alincourt MS; Manuel ER; Kaltcheva T; Tsai W; Blazar BR; Diamond DJ; Melstrom LG
Cancer Gene Ther; 2020 Apr; 27(3-4):235-245. PubMed ID: 30824815
[TBL] [Abstract][Full Text] [Related]
10. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
12. Advanced age negatively impacts survival in an experimental brain tumor model.
Ladomersky E; Zhai L; Gritsina G; Genet M; Lauing KL; Wu M; James CD; Wainwright DA
Neurosci Lett; 2016 Sep; 630():203-208. PubMed ID: 27493076
[TBL] [Abstract][Full Text] [Related]
13. High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V; Bianconi F; Siggillino A; Vannucci J; Baglivo S; Berti V; Tofanetti FR; Reda MS; Bellezza G; Mandarano M; Belladonna ML; Metro G; Chiari R; Sidoni A; Puma F; Minotti V; Roila F
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671892
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
15. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
16. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
17. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
